Clinical Trial Update: RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating RO4929097 in combination with letrozole for postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer (includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Stage Iiia Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Status: TERMINATED